FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968244461> ?p ?o ?g. }

• W2968244461 endingPage "1808" @default.
• W2968244461 startingPage "1799" @default.
• W2968244461 abstract "The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.Randomized, controlled, double-blind, phase 3 trial. Hospitalized patients with hospital-acquired/ventilator-associated pneumonia, complicated intraabdominal infection, or complicated urinary tract infection caused by imipenem-nonsusceptible (but colistin- and imipenem/relebactam-susceptible) pathogens were randomized 2:1 to 5-21 days imipenem/relebactam or colistin+imipenem. Primary endpoint: favorable overall response (defined by relevant endpoints for each infection type) in the modified microbiologic intent-to-treat (mMITT) population (qualifying baseline pathogen and ≥1 dose study treatment). Secondary endpoints: clinical response, all-cause mortality, and treatment-emergent nephrotoxicity. Safety analyses included patients with ≥1 dose study treatment.Thirty-one patients received imipenem/relebactam and 16 colistin+imipenem. Among mITT patients (n = 21 imipenem/relebactam, n = 10 colistin+imipenem), 29% had Acute Physiology and Chronic Health Evaluation II scores >15, 23% had creatinine clearance <60 mL/min, and 35% were aged ≥65 years. Qualifying baseline pathogens: Pseudomonas aeruginosa (77%), Klebsiella spp. (16%), other Enterobacteriaceae (6%). Favorable overall response was observed in 71% imipenem/relebactam and 70% colistin+imipenem patients (90% confidence interval [CI] for difference, -27.5, 21.4), day 28 favorable clinical response in 71% and 40% (90% CI, 1.3, 51.5), and 28-day mortality in 10% and 30% (90% CI, -46.4, 6.7), respectively. Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively.Imipenem/relebactam is an efficacious and well-tolerated treatment option for carbapenem-nonsusceptible infections.NCT02452047." @default.
• W2968244461 created "2019-08-22" @default.
• W2968244461 creator A5008776510 @default.
• W2968244461 creator A5011664661 @default.
• W2968244461 creator A5012146771 @default.
• W2968244461 creator A5013718821 @default.
• W2968244461 creator A5017414691 @default.
• W2968244461 creator A5019544224 @default.
• W2968244461 creator A5022689608 @default.
• W2968244461 creator A5028174729 @default.
• W2968244461 creator A5028746842 @default.
• W2968244461 creator A5029950456 @default.
• W2968244461 creator A5033696100 @default.
• W2968244461 creator A5042094125 @default.
• W2968244461 creator A5042149117 @default.
• W2968244461 creator A5043017232 @default.
• W2968244461 creator A5046046038 @default.
• W2968244461 creator A5065796311 @default.
• W2968244461 creator A5073235420 @default.
• W2968244461 creator A5086890870 @default.
• W2968244461 date "2019-08-10" @default.
• W2968244461 modified "2023-10-06" @default.
• W2968244461 title "RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections" @default.
• W2968244461 cites W1929522087 @default.
• W2968244461 cites W2007732838 @default.
• W2968244461 cites W2103077615 @default.
• W2968244461 cites W2110880963 @default.
• W2968244461 cites W2118836068 @default.
• W2968244461 cites W2123859227 @default.
• W2968244461 cites W2145111808 @default.
• W2968244461 cites W2149186506 @default.
• W2968244461 cites W2168502103 @default.
• W2968244461 cites W2203490562 @default.
• W2968244461 cites W2252374742 @default.
• W2968244461 cites W2473016454 @default.
• W2968244461 cites W2505961383 @default.
• W2968244461 cites W2534752245 @default.
• W2968244461 cites W2621162085 @default.
• W2968244461 cites W2765962920 @default.
• W2968244461 cites W2783246132 @default.
• W2968244461 cites W2789743410 @default.
• W2968244461 cites W2793390003 @default.
• W2968244461 cites W2796172180 @default.
• W2968244461 cites W2797777892 @default.
• W2968244461 cites W2898081316 @default.
• W2968244461 cites W2911566892 @default.
• W2968244461 doi "https://doi.org/10.1093/cid/ciz530" @default.
• W2968244461 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7156774" @default.
• W2968244461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31400759" @default.
• W2968244461 hasPublicationYear "2019" @default.
• W2968244461 type Work @default.
• W2968244461 sameAs 2968244461 @default.
• W2968244461 citedByCount "231" @default.
• W2968244461 countsByYear W29682444612018 @default.
• W2968244461 countsByYear W29682444612019 @default.
• W2968244461 countsByYear W29682444612020 @default.
• W2968244461 countsByYear W29682444612021 @default.
• W2968244461 countsByYear W29682444612022 @default.
• W2968244461 countsByYear W29682444612023 @default.
• W2968244461 crossrefType "journal-article" @default.
• W2968244461 hasAuthorship W2968244461A5008776510 @default.
• W2968244461 hasAuthorship W2968244461A5011664661 @default.
• W2968244461 hasAuthorship W2968244461A5012146771 @default.
• W2968244461 hasAuthorship W2968244461A5013718821 @default.
• W2968244461 hasAuthorship W2968244461A5017414691 @default.
• W2968244461 hasAuthorship W2968244461A5019544224 @default.
• W2968244461 hasAuthorship W2968244461A5022689608 @default.
• W2968244461 hasAuthorship W2968244461A5028174729 @default.
• W2968244461 hasAuthorship W2968244461A5028746842 @default.
• W2968244461 hasAuthorship W2968244461A5029950456 @default.
• W2968244461 hasAuthorship W2968244461A5033696100 @default.
• W2968244461 hasAuthorship W2968244461A5042094125 @default.
• W2968244461 hasAuthorship W2968244461A5042149117 @default.
• W2968244461 hasAuthorship W2968244461A5043017232 @default.
• W2968244461 hasAuthorship W2968244461A5046046038 @default.
• W2968244461 hasAuthorship W2968244461A5065796311 @default.
• W2968244461 hasAuthorship W2968244461A5073235420 @default.
• W2968244461 hasAuthorship W2968244461A5086890870 @default.
• W2968244461 hasBestOaLocation W29682444611 @default.
• W2968244461 hasConcept C126322002 @default.
• W2968244461 hasConcept C197934379 @default.
• W2968244461 hasConcept C2776685102 @default.
• W2968244461 hasConcept C2779259085 @default.
• W2968244461 hasConcept C2779631663 @default.
• W2968244461 hasConcept C3019249092 @default.
• W2968244461 hasConcept C501593827 @default.
• W2968244461 hasConcept C71924100 @default.
• W2968244461 hasConcept C86803240 @default.
• W2968244461 hasConcept C89423630 @default.
• W2968244461 hasConcept C94665300 @default.
• W2968244461 hasConceptScore W2968244461C126322002 @default.
• W2968244461 hasConceptScore W2968244461C197934379 @default.
• W2968244461 hasConceptScore W2968244461C2776685102 @default.
• W2968244461 hasConceptScore W2968244461C2779259085 @default.
• W2968244461 hasConceptScore W2968244461C2779631663 @default.
• W2968244461 hasConceptScore W2968244461C3019249092 @default.
• W2968244461 hasConceptScore W2968244461C501593827 @default.
• W2968244461 hasConceptScore W2968244461C71924100 @default.

• next